OALib Journal期刊
Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study
DOI: 10.1186/s12969-017-0212-y
Alberto Martini ,
Anasuya Hazra ,
Charles A. Mebus ,
Christine Alvey ,
Daniel J. Kingsbury ,
Daniel J. Lovell ,
Elzbieta Smolewska ,
Gerd Horneff ,
Hermine I. Brunner ,
Ivan Foeldvari ,
Manisha Lamba ,
Min Wang ,
Nicolino Ruperto ,
Nikolay Tzaribachev ,
Ricardo Suehiro ,
Richard K. Vehe ,
Rong Wang ,
Sriram Krishnaswami ,
Thomas C. Stock ,
Zbigniew Zuber ,
for the Pediatric Rheumatology International Trials Organization (PRINTO) ,
the Pediatric Rheumatology Collaborative Study Group (PRCSG) Keywords: Janus kinase inhibitor , Juvenile idiopathic arthritis , Tofacitinib , Pediatric , Pharmacokinetics , Safety , Dosing
Abstract:
The online version of this article (10.1186/s12969-017-0212-y) contains supplementary material, which is available to authorized users
Full-Text
Contact Us
service@oalib.com
QQ:3279437679
WhatsApp +8615387084133
